tradingkey.logo

Rapid Micro Biosystems Inc

RPID
查看詳細走勢圖
3.870USD
+0.190+5.16%
收盤 02/06, 16:00美東報價延遲15分鐘
171.48M總市值
虧損本益比TTM

Rapid Micro Biosystems Inc

3.870
+0.190+5.16%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+5.16%

5天

-12.64%

1月

+14.50%

6月

+13.49%

今年開始到現在

+33.45%

1年

+24.84%

查看詳細走勢圖

TradingKey Rapid Micro Biosystems Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Rapid Micro Biosystems Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力較大。當前估值合理,在醫療設備與耗材行業排名98/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為8.00。中期看,股價處於上升通道。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Rapid Micro Biosystems Inc評分

相關信息

行業排名
98 / 205
全市場排名
261 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Rapid Micro Biosystems Inc亮點

亮點風險
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
業績高增長
公司營業收入穩步增長,連續3年增長63.72%
業績增長期
公司處於發展階段,最新年度總收入28.05M美元
估值低估
公司最新PE估值-3.88,處於3年歷史低位
機構減倉
最新機構持股23.36M股,環比減少7.42%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉978.78K股

分析師目標

基於 4 分析師
買入
評級
8.000
目標均價
+117.39%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Rapid Micro Biosystems Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Rapid Micro Biosystems Inc簡介

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
公司代碼RPID
公司Rapid Micro Biosystems Inc
CEOSpignesi (Robert)
網址https://www.rapidmicrobio.com/
KeyAI